Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
Clin Chem. 2010 Jan;56(1):21-33. doi: 10.1373/clinchem.2009.133801. Epub 2009 Nov 19.
Stroke is a devastating condition encompassing a wide range of pathophysiological entities that include thrombosis, hemorrhage, and embolism. Current diagnosis of stroke relies on physician clinical examination and is further supplemented with various neuroimaging techniques. A single set or multiple sets of blood biomarkers that could be used in an acute setting to diagnosis stroke, differentiate between stroke types, or even predict an initial/reoccurring stroke would be extremely valuable.
We discuss the current classification, diagnosis, and treatment of stroke, focusing on use of novel biomarkers (either solitary markers or multiple markers within a panel) that have been studied in a variety of clinical settings.
The current diagnosis of stroke remains hampered and delayed due to lack of a suitable mechanism for rapid (ideally point-of-care), accurate, and analytically sensitive biomarker-based testing. There is a clear need for further development and translational research in this area. Potential biomarkers identified need to be transitioned quickly into clinical validation testing for further evaluation in an acute stroke setting; to do so would impact and improve patient outcomes and quality of life.
中风是一种严重的疾病，涵盖了广泛的病理生理实体，包括血栓形成、出血和栓塞。目前中风的诊断依赖于医生的临床检查，并进一步辅以各种神经影像学技术。如果有一种或多种血液生物标志物可以在急性情况下用于诊断中风、区分中风类型，甚至预测初次/再次中风，那将是非常有价值的。
我们讨论了中风的当前分类、诊断和治疗，重点介绍了在各种临床环境中研究过的新型生物标志物（单一标志物或标志物组合）。
目前中风的诊断仍然受到阻碍和延迟，因为缺乏一种合适的机制来进行快速（理想情况下是床边）、准确和分析敏感的基于生物标志物的检测。在这一领域显然需要进一步的开发和转化研究。需要快速将已确定的潜在生物标志物转化为临床验证测试，以便在急性中风情况下进一步评估；这样做将影响和改善患者的预后和生活质量。
